Belite Bio, Inc (BLTE)
BLTE
193.61
+22.52 (+13.16%)
FUNDAMENTALS
SectorHealthcare
IndustryBiotechnology
Market Cap$7.80B
P/E Ratio—
52W High200.00
52W Low64.80
Dividend Yield—
ANALYSIS
SMA 20164.7
SMA 50158.22
Volatility (ann.)50.69%
RSI (14)71.23
Beta (vs SPY)1.1
MACD (12,26,9)3.27 / 1.28
Bollinger (20,2)145.25 – 184.14
FINANCIALS — QUARTERLY
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Operating Income | $-34,907,000 | $-32,684,000 | $-28,077,000 | $-23,018,000 |
| Net Income | $-28,412,000 | $-26,938,000 | $-25,324,000 | $-21,690,000 |
| Diluted EPS | -0.70 | -0.68 | -0.70 | -0.65 |
EARNINGS
Next Earnings DateNov 09, 2026
Aug 13, 2026
est -0.78 /
act -0.70
+9.9%
May 20, 2026
est -0.64 /
act -0.68
-5.8%
Mar 02, 2026
est -0.54 /
act -0.70
-30.3%
Nov 10, 2025
est -0.49 /
act -0.65
-32.6%
Aug 11, 2025
est -0.42 /
act -0.50
-19.8%
May 14, 2025
est -0.36 /
act -0.45
-23.3%
ANALYST COVERAGE
No analyst coverage available.
OWNERSHIP & INSIDERS
Insiders—
Institutions—
Short % of Float—
Short Ratio—
TOP INSTITUTIONAL HOLDERS
No holder data available.
RECENT INSIDER TRANSACTIONS
No insider transactions available.
NEWS
Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run
Simply Wall St.